VIDEO: Genentech shares positive study data ahead of Susvimo relaunch
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS, of Genentech/Roche shares an update on Susvimo and the port delivery platform.
Quezada-Ruiz reviewed positive study outcomes seen with Susvimo (ranibizumab injection 100 mg/mL, Genentech) for the treatment of neovascular age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
“Susvimo is the only sustained delivery and continuous drug delivery system that has shown positive data across three different phase 3 pivotal trials in DR, DME and neovascular AMD,” he said. “We are very excited for the U.S. relaunch, and we are very excited as well to bring this therapy to market for patients afflicted with neovascular AMD, DME and DR around the world.”
Genentech announced this week that it is reintroducing Susvimo for patients with wet AMD after a voluntary recall in the U.S. in 2022.
Collapse
Quezada-Ruiz C. Update on port delivery platform for retinal diseases. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Click Here to Manage Email Alerts